A Wiedemann, K Becher, A Manseck, J Stein, M Fröhner, C Fiebig, A Piotrowski, R Kirschner-Hermanns, A Bannowsky, S Wirz, J Salem, T H Kuru
{"title":"[Androgen deprivation therapy of prostate cancer from a geriatric perspective].","authors":"A Wiedemann, K Becher, A Manseck, J Stein, M Fröhner, C Fiebig, A Piotrowski, R Kirschner-Hermanns, A Bannowsky, S Wirz, J Salem, T H Kuru","doi":"10.1007/s00391-025-02454-0","DOIUrl":null,"url":null,"abstract":"<p><p>Androgen deprivation therapy (ADT) for prostate cancer is carried out in a palliative approach in symptomatic geriatric patients. Testosterone synthesis is suppressed using a dual therapy principle with luteinising hormone-releasing hormone (LH-RH) analogues or antagonists of LH-RH, in addition to modern antiandrogens. Additional administration of taxanes is initially possible in cases of high tumor burden and aggressive tumor biology, which is otherwise reserved for castration-resistant prostate cancer. The ADT is a systemic therapy for all testosterone-dependent processes and can lead to hot flushes, gynecomastia, osteoporosis, sarcopenia, anemia, falls, cognitive decline, depression, metabolic syndrome, increased cardiovascular events and many drug interactions. In patients identified as geriatric, ADT should therefore only be used after a thorough risk-benefit analysis.</p>","PeriodicalId":49345,"journal":{"name":"Zeitschrift Fur Gerontologie Und Geriatrie","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift Fur Gerontologie Und Geriatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00391-025-02454-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Androgen deprivation therapy (ADT) for prostate cancer is carried out in a palliative approach in symptomatic geriatric patients. Testosterone synthesis is suppressed using a dual therapy principle with luteinising hormone-releasing hormone (LH-RH) analogues or antagonists of LH-RH, in addition to modern antiandrogens. Additional administration of taxanes is initially possible in cases of high tumor burden and aggressive tumor biology, which is otherwise reserved for castration-resistant prostate cancer. The ADT is a systemic therapy for all testosterone-dependent processes and can lead to hot flushes, gynecomastia, osteoporosis, sarcopenia, anemia, falls, cognitive decline, depression, metabolic syndrome, increased cardiovascular events and many drug interactions. In patients identified as geriatric, ADT should therefore only be used after a thorough risk-benefit analysis.
期刊介绍：
The fact that more and more people are becoming older and are having a significant influence on our society is due to intensive geriatric research and geriatric medicine in the past and present. The Zeitschrift für Gerontologie und Geriatrie has contributed to this area for many years by informing a broad spectrum of interested readers about various developments in gerontology research. Special issues focus on all questions concerning gerontology, biology and basic research of aging, geriatric research, psychology and sociology as well as practical aspects of geriatric care.
Target group: Geriatricians, social gerontologists, geriatric psychologists, geriatric psychiatrists, nurses/caregivers, nurse researchers, biogerontologists in geriatric wards/clinics, gerontological institutes, and institutions of teaching and further or continuing education.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
